InsidersTradesSigma
Follow the 셀로맥스사이언스 stock price and the full management transaction log of the company, a publicly traded company based in South Korea. Shares are listed on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 셀로맥스사이언스 has recorded 15 reports. Market capitalisation: €45.4bn. The latest transaction was reported on 7 April 2026 (Purchase). Among the most active insiders: 서정민. All data is openly available.
15
Insider Decl.
n/a
Thresholds
n/a
15 ops.
Buy Volume
n/a
n/a
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,973 of 29,063 companies
66.5
score / 100
Value61
Quality72
FCF yld3.5%
Earn yld6.5%
EV/EBITDA11.5x
ROE7.6%
Gross mgn48%
Net mgn13%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 7 April 2026
Declarations15 total
385,328 sharesKRXDART:20241217000406
15 of 15 declarations
Acerca de 셀로맥스사이언스
Cellomax Science es una empresa de atención médica y farmacéutica que cotiza en el mercado XKRX. Se enfoca en el desarrollo de soluciones innovadoras en el sector de las ciencias de la vida.